ClinicalTrials.gg
TerminatedNCT01499667TOFIINGOUpdated Aug 8, 2014Results posted

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

A Phase 3 interventional study of Fingolimod and Placebo in Relapsing Remitting Multiple Sclerosis (RRMS), sponsored by Novartis Pharmaceuticals. Terminated at 44 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-08.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Based on recent publications, determination of natalizumub washout period was no longer relevant.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
10th of 19
142 · median 142
Started
2011
with 5 others
Phase 3
5 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 10th largest by enrollment, is one of 6 that started in 2011, is one of 5 in phase 3, and was the 7th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.

Read the detailed description

Patient were screened, signed an informed consent at visit 1, at the 2nd visit, all patient received a baseline infusion of Natalizumub and subsequently randomized to one of 3 treatment arms. At the randomization visit, the Washout Phase started, and eligible patients were randomized 1:1:1 to one of three treatment groups:

  • 8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod,
  • 12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod, or
  • 16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod.
03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis (RRMS)

Keywords

  • Relapsing remitting multiple sclerosis
  • multiple sclerosis (MS)
  • safety
  • tolerability
  • health outcomes
  • fingolimod
  • disease control
  • MRI
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must:

  • Have relapsing remitting multiple sclerosis
  • Have been on treatment with natalizumab for at least 6 months prior to screening and discontinuation is an option.

Exclusion criteria

Exclusion Criteria:

Patients with:

  • History of chronic immune disease
  • Crohn's disease
  • Certain cancers
  • Uncontrolled diabetes
  • Certain eye disorders
  • Negative for varicella-zoster virus IgG antibodies
  • Certain hepatic conditions
  • Low white blood cell count
  • On certain medications or heart medications
  • Resting heart rate less than 45 bpm.
  • Certain heart conditions or certain lung conditions
  • Inability to undergo MRI scans

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    8-week washout + Fingolimod (FTY720)

    8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day

    Drug: Fingolimod

  • Experimental
    12-week washout + Fingolimod (FTY720)

    12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day

    Drug: Fingolimod · Drug: Placebo

  • Experimental
    16-week washout + Fingolimod (FTY720)

    16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day

    Drug: Fingolimod · Drug: Placebo

Interventions

  • Fingolimod 0.5 mg capsules for oral administration once daily

  • DrugPlacebo

    Matching placebo in capsules for oral administration once daily.

06

What researchers measure

Primary outcomes

  1. Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment

    Active lesions were measured on brain MRI scans, performed at week 8, compared to the prior scan. The primary variable was analyzed by fitting a negative binomial regression model adjusted for washout group.

    Time frame: Number of active T2 lesions from last natalizumab dose through 8 weeks of fingolimod treatment

Secondary outcomes

  1. Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment

    Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated from baseline to beginning of treatment.

    Time frame: 8, 12 and 16 weeks (number of active T2 lesions during the washout period only)

  2. Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment

    Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated for first 8 weeks of fingolimod treatment.

    Time frame: Number of active T2 lesions during 8 wks of fingolimod treatment

  3. Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)

    Lesions will be measured by MRIs and the number of active (new or newly enlarging) T2 lesions will be calculated for 24 weeks from baseline.

    Time frame: Baseline up to 24 weeks

  4. Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group

    Kurtzke's Expanded Disability Status Scale (EDSS) measures the changes in neurologic impairment, either chronic (progression over time), or acute (MS relapses). The EDSS steps range from 0 (normal) to 10 (death due to MS). Relapse severity is assessed based on severity of neurologic impairment as evaluated using the EDSS.

    Time frame: Baseline to week 16 and week 32

  5. Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion

    Gadolinium-enhancing lesions will be measured on post-contrast T1-weighted brain MRI scans

    Time frame: 8 weeks and 24 weeks

  6. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period

    Adverse events were summarized by the number of patients having any adverse event overall.

    Time frame: Baseline to maximum of 16 weeks

  7. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment

    Adverse events were summarized by the number of patients having any adverse event overall.

    Time frame: Baseline to maximum of 16 weeks

07

Results

Posted Apr 4, 2014
Limitations and caveats
Study was terminated due to new data on nataluzimab washout prior to treatment with other disease modifying treatments. The power to detect statistically significant differences between the washout groups based on the (-)binomial is estimated 30-40%.

Participant flow

Of the 158 patients screened, 142 patients were randomized.

Participant flow — Overall Study
Milestone8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Started504250
Full analysis set (fas)494250
Modified full analysis set412939
Completed413140
Not completed91110
Withdrew: Administrative problems455
Withdrew: Protocol violation132
Withdrew: Adverse event022
Withdrew: Withdrawal by subject211
Withdrew: Lack of efficacy200

Outcome measures

PrimaryNumber of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment

Active lesions were measured on brain MRI scans, performed at week 8, compared to the prior scan. The primary variable was analyzed by fitting a negative binomial regression model adjusted for washout group.

Time frame:
Number of active T2 lesions from last natalizumab dose through 8 weeks of fingolimod treatment
Reported as:
Mean · Count of Active T2 Lesions
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment
Count of Active T2 Lesions8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment2.1 ± 7.241.7 ± 3.788.2 ± 16.81
SecondaryNumber of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment

Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated from baseline to beginning of treatment.

Time frame:
8, 12 and 16 weeks (number of active T2 lesions during the washout period only)
Reported as:
Mean · Count of active T2 lesions
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment
Count of active T2 lesions8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) up to the Initiation of Fingolimod Treatment0.4 ± 2.712.1 ± 11.153.6 ± 7.54
SecondaryNumber of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment

Lesions were measured by MRIs and the number of active (new or newly enlarging) T2 lesions was calculated for first 8 weeks of fingolimod treatment.

Time frame:
Number of active T2 lesions during 8 wks of fingolimod treatment
Reported as:
Mean · Count of Active T2 Lesions
Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment
Count of Active T2 Lesions8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Number of Active (New or Newly Enlarging) T2 Lesions During the First 8 Weeks of Fingolimod Treatment1.5 ± 4.562.1 ± 5.504.2 ± 10.24
SecondaryNumber of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)

Lesions will be measured by MRIs and the number of active (new or newly enlarging) T2 lesions will be calculated for 24 weeks from baseline.

Time frame:
Baseline up to 24 weeks
Reported as:
Mean · Count of Active T2 Lesions
Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)
Count of Active T2 Lesions8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Number of Active (New or Newly Enlarging) T2 Lesions During the 24 Weeks After the Last Natalizumab Infusion (Baseline)3.2 ± 10.074.4 ± 16.017.7 ± 16.28
SecondaryChange From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group

Kurtzke's Expanded Disability Status Scale (EDSS) measures the changes in neurologic impairment, either chronic (progression over time), or acute (MS relapses). The EDSS steps range from 0 (normal) to 10 (death due to MS). Relapse severity is assessed based on severity of neurologic impairment as evaluated using the EDSS.

Time frame:
Baseline to week 16 and week 32
Reported as:
Mean · Units on a scale
Change From Baseline in Expanded Disability Status Scale (EDSS) by Washout Group
Units on a scale8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Week 16 (n=40, 33, 39)0.11 ± 0.330-0.03 ± 0.5290.23 ± 0.706
Week 32 (n= 40,30,39)0.11 ± 0.625-0.13 ± 0.5240.08 ± 0.748
SecondaryCumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion

Gadolinium-enhancing lesions will be measured on post-contrast T1-weighted brain MRI scans

Time frame:
8 weeks and 24 weeks
Reported as:
Mean · Number of Gd enhanced T1 Lesions
Cumulative Number of Gadolinium-enhancing T1 Lesions From the Last Natalizumab Infusion
Number of Gd enhanced T1 Lesions8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Week 8 (n=1,1,0)25.0 ± 02.0 ± 0NA ± NA
Week 24 (n=10,12,21)6.3 ± 9.453.4 ± 4.543.6 ± 4.49
SecondaryNumber of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period

Adverse events were summarized by the number of patients having any adverse event overall.

Time frame:
Baseline to maximum of 16 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Washout Period
participants8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Any Adverse Events131225
Serious Adverse Events001
Death000
SecondaryNumber of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment

Adverse events were summarized by the number of patients having any adverse event overall.

Time frame:
Baseline to maximum of 16 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) and Death During Fingolimod Treatment
participants8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Any Adverse Events352028
Serious Adverse Events253
Death000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
8-week Washout + Fingolimod (FTY720)—2/50 (4%)17/50 (34%)
12-week Washout + Fingolimod (FTY720)—5/42 (11.9%)7/42 (16.7%)
16-week Washout + Fingolimod (FTY720)—4/50 (8%)14/50 (28%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
Event8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
Multiple sclerosis relapseNervous system disorders0/500/422/50
Cholecystitis acuteHepatobiliary disorders0/501/420/50
CholelithiasisHepatobiliary disorders0/501/420/50
PharyngitisInfections and infestations0/501/420/50
Heart rate decreasedInvestigations0/501/420/50
EpilepsyNervous system disorders0/501/420/50
SyncopeNervous system disorders0/501/420/50
Depression suicidalPsychiatric disorders0/501/420/50
BradycardiaCardiac disorders0/500/421/50
PneumoniaInfections and infestations1/500/420/50
Most frequent other events
Most frequent other events
Event8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)
HeadacheNervous system disorders5/503/4210/50
NasopharyngitisInfections and infestations7/501/422/50
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/500/420/50
Oral herpesInfections and infestations1/503/421/50
SinusitisInfections and infestations2/501/423/50
Urinary tract infectionInfections and infestations3/501/420/50
MyalgiaMusculoskeletal and connective tissue disorders3/500/420/50
DizzinessNervous system disorders3/501/423/50
DepressionPsychiatric disorders1/501/423/50
CoughRespiratory, thoracic and mediastinal disorders3/500/421/50

Baseline characteristics

Randomized set includes all subjects who receive a randomization number, regardless of whether or not they receive study medication.

Age, Continuous
Age, Continuous(Years)8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)Total
Mean41.2 ± 10.10241.9 ± 7.44541.8 ± 8.55241.6 ± 8.780
Sex: Female, Male
Sex: Female, Male(Participants)8-week Washout + Fingolimod (FTY720)12-week Washout + Fingolimod (FTY720)16-week Washout + Fingolimod (FTY720)Total
Female39213292
Male11211850
08

Study locations

44 sites
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    Heidelberg, Victoria 3084, Australia
  • Novartis Investigative Site
    Vienna, 1010, Austria
  • Novartis Investigative Site
    Prague 5, 150 00, Czech Republic
  • Novartis Investigative Site
    Praha 2, 128 08, Czech Republic
  • Novartis Investigative Site
    Teplice, 415 29, Czech Republic
  • Novartis Investigative Site
    Helsinki, 00100, Finland
  • Novartis Investigative Site
    Ostfildern, Baden-Wuerttemberg 73760, Germany
  • Novartis Investigative Site
    Bad Mergentheim, 97980, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 12163, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bochum, 44791, Germany
  • Novartis Investigative Site
    Celle, 29223, Germany
  • Novartis Investigative Site
    Erbach, 64711, Germany
  • Novartis Investigative Site
    Erfurt, 99089, Germany
  • Novartis Investigative Site
    Hamburg, 22083, Germany
  • Novartis Investigative Site
    Itzehoe, 25524, Germany
  • Novartis Investigative Site
    Kandel, 76870, Germany
  • Novartis Investigative Site
    Krefeld, 47805, Germany
  • Novartis Investigative Site
    Leipzig, 04275, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Neuburg, 86633, Germany
  • Novartis Investigative Site
    Neuruppin, 16816, Germany
  • Novartis Investigative Site
    Rüdersdorf, 15562, Germany
  • Novartis Investigative Site
    Siegen, 57076, Germany
  • Novartis Investigative Site
    Ulm, 89073, Germany
  • Novartis Investigative Site
    Athens, GR 115 25, Greece
  • Novartis Investigative Site
    Ioannina, GR 455 00, Greece
  • Novartis Investigative Site
    Thessaloniki, GR 570 10, Greece
  • Novartis Investigative Site
    Athens, GR 151 25, Greece
  • Novartis Investigative Site
    Athens, GR-106 76, Greece
  • Novartis Investigative Site
    Budapest, 1074, Hungary
  • Novartis Investigative Site
    Budapest, 1085, Hungary
  • Novartis Investigative Site
    Ashkelon, 78278, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Milano, MI 20132, Italy
  • Novartis Investigative Site
    Cefalù, PA 90015, Italy
  • Novartis Investigative Site
    Málaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Sevilla, Andalucia 41009, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08025, Spain
  • Novartis Investigative Site
    Madrid, 28046, Spain
  • Novartis Investigative Site
    Basel, 4031, Switzerland
09

References and documents

Publications

  • Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A, Zhang Y, Wiendl H, Tomic D. alpha4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm. 2017 Aug 25;4(5):e388. doi: 10.1212/NXI.0000000000000388. eCollection 2017 Sep. PubMed 28856176 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Dec 26, 2011
Start
Sep 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Apr 4, 2014
Last update
Aug 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01499667
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Sep 2011
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Apr 4, 2014
Last update
Aug 8, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion